Patents Examined by Julie Wu
  • Patent number: 12122842
    Abstract: Embodiments of the present disclosure relate to antigen-binding affinity reagents for an analyte-of-interest. In particular, the present disclosure provides novel binding proteins (antibodies), including derivatives and fragments thereof, that target human CD30.
    Type: Grant
    Filed: September 27, 2023
    Date of Patent: October 22, 2024
    Assignee: R&D Systems, Inc.
    Inventors: Cyrus B. Munshi, Kerri Ann Bostrom, Julie Anne Werner, Lori Ann Heitkamp
  • Patent number: 12121540
    Abstract: Methods and compositions using novel Cbl inhibitors for supporting engraftment of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions using novel Cbl inhibitors for the propagation of cells desirable for use in cell-based immunotherapies.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: October 22, 2024
    Assignee: NURIX THERAPEUTICS, INC.
    Inventors: Jennifa Gosling, Arthur Sands, Sarah Anne Whelan, Cristiana Guiducci
  • Patent number: 12116407
    Abstract: Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: October 15, 2024
    Assignee: Academia Sinica
    Inventors: Shie-Liang Hsieh, Pei-Shan Sung, Ming-Ting Huang, An-Suei Yang, Chung-Ming Yu
  • Patent number: 12115193
    Abstract: The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.
    Type: Grant
    Filed: October 5, 2023
    Date of Patent: October 15, 2024
    Assignee: Io Therapeutics, Inc.
    Inventors: Martin E. Sanders, Vidyasagar Vuligonda
  • Patent number: 12102689
    Abstract: The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: October 1, 2024
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: David Rabuka, Jesse M. Mcfarland, Penelope M. Drake, Robyn M. Barfield
  • Patent number: 12098200
    Abstract: Provided herein are single domain antibodies (sdAbs) configured for passing the blood brain barrier in a human or mammal brain. Methods of using such sdAbs are also described herein, such as methods of binding to brain cells, binding with and transporting other sdAbs with beneficial functionalities, binding to and transporting biochemical or pharmaceutical species with beneficial functionalities, and treating, diagnosing, or prophylactically treating a disease, malignancy, or condition.
    Type: Grant
    Filed: October 12, 2022
    Date of Patent: September 24, 2024
    Assignee: National Technology & Engineering Solutions of Sandia, LLC
    Inventors: Brooke Nicole Harmon, Maxwell Stefan, Jennifer Schwedler, Christopher Sumner, Yooli Kim Light, Catherine Margaret Mageeney
  • Patent number: 12084520
    Abstract: Disclosed is a monoclonal antibody that specifically binds BCMA, or an antigen binding fragment thereof, and its use in treating cancers such as multiple myeloma. Also disclosed is a monoclonal antibody that specifically binds CD3, or an antigen binding fragment thereof, and its use in treating or alleviating an inflammatory disease, an autoimmune disease, or transplantation rejection. Further disclosed is an anti-BCMA/CD3 bispecific antibody, and its use in treating diseases such as cancers.
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: September 10, 2024
    Assignee: BEIJING MABWORKS BIOTECH CO., LTD
    Inventors: Fangjie Liu, Jiangmei Li, Wenqi Hu, Feng Li
  • Patent number: 12084511
    Abstract: The present invention relates to a compound comprising a first polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of GFTFSDYW (SEQ ID NO: 1), IRLKSNNYAA (SEQ ID NO: 2) and TFGNSFAY (SEQ ID NO: 3), a second polypeptide sequence comprising at least three different amino acid sequences selected from the group consisting of TGAVTTNNY (SEQ ID NO: 4), GTN (SEQ ID NO: 5) and ALWYSNHWV (SEQ ID NO: 6), or a variant of any one of said amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 6 having a different amino acid at one position, wherein said compound or variant is capable of binding to tumour-associated Mucin-1 (TA-MUC1).
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: September 10, 2024
    Assignee: Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Inventors: Edgar Schmitt, Horst Kunz, Natascha Stergiou, Nikola Gaidzik
  • Patent number: 12084403
    Abstract: In one aspect, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein.
    Type: Grant
    Filed: February 23, 2023
    Date of Patent: September 10, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Kyoji Tsuchikama, Yasuaki Anami, Chisato Tsuchikama, Ningyang Zhang, Zhiqiang An
  • Patent number: 12065503
    Abstract: Provided is a stable pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, and the like. In the pharmaceutical composition comprising a labeling moiety-anti-human antibody Fab fragment conjugate, citric acid, phosphoric acid, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid or trishydroxymethyl aminomethane is added as a buffering agent, sucrose or glycerin is added as a stabilizer, a nonionic surfactant is added, and the pH is adjusted to 6.5 to 7.5. This enables suppression of generation of multimers and insoluble subvisible particles during preservation of the labeling moiety-anti-human antibody Fab fragment conjugate.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: August 20, 2024
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Jumpei Suemitsu, Megumi Ikeda, Moe Kohno
  • Patent number: 12060427
    Abstract: Presented herein are novel monoclonal cMET binding agents that are conjugated to pyrrolobenzodiazepine toxins, composition thereof and uses thereof for the treatment of cancer.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: August 13, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORAT
    Inventors: Julia Coronella, Marco Gymnopoulos, Vincent Blot, Ryo Fujita, Roland Newman
  • Patent number: 12059444
    Abstract: The present invention relates to an oncolytic virus encoding a CTLA-4 inhibitor, such as an anti-CTLA-4 antibody, or an antigen binding fragment thereof.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: August 13, 2024
    Assignee: Replimune Limited
    Inventor: Robert Stuart Coffin
  • Patent number: 12043670
    Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: July 23, 2024
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryan Henry, Thiwanka Samarakoon, Nathan Fishkin, Ping Zhu, Ermira Pazolli, James Palacino, Juan C. Almagro
  • Patent number: 12029736
    Abstract: The invention provides, camptothecins, camptothecin payloads, and camptothecin conjugates, methods of preparing and using, and intermediates useful in the preparation thereof. Also provided herein are methods of treating cancer and autoimmune diseases with the camptothecin conjugates described herein.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: July 9, 2024
    Assignee: MediBoston Limited
    Inventor: Wei Li
  • Patent number: 12030954
    Abstract: Provided is an antibody or an antigen-binding fragment thereof, having one or more properties selected from the group consisting of: 1) being capable of binding to an AXL protein by a KD value of 1×10?8 M or lower; 2) being capable of specifically recognizing an AXL protein expressed on a cell surface; and 3) being capable of mediating internalization after binding to the AXL protein expressed on the cell surface. The antibody may further used for constructing an immunoconjugate. The antibody and the immunoconjugate may inhibit the proliferation of tumor cells.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: July 9, 2024
    Assignees: HANGZHOU SUMGEN BIOTECH CO., LTD., SUMGEN MAB (BEIJING) BIOTECH CO., LTD.
    Inventors: Ming Lv, Xiaoran Ding, Shiwei Miao, Bin Tan, Xuegong Wang
  • Patent number: 12011436
    Abstract: The present invention is related to compounds, methods, compositions and uses that are able to restore responsiveness to immunotherapy, in particular immune check point inhibitors or anti-cancer vaccine or to anti-angiogenesis treatment.
    Type: Grant
    Filed: November 1, 2018
    Date of Patent: June 18, 2024
    Assignees: CALLIDITAS THERAPEUTICS SUISSE SA, UNIVERSITY OF SOUTHAMPTON
    Inventors: Philippe Wiesel, Freddy Heitz, Gareth Thomas, Christopher Hanley, Kirsty Ford
  • Patent number: 12011439
    Abstract: The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2022
    Date of Patent: June 18, 2024
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Shijie Li, Venkat Reddy Mali, Rajinder Singh, Ju Yang, Penglie Zhang
  • Patent number: 11987632
    Abstract: The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: May 21, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Tina Weinzierl, Lydia Jasmin Hanisch, Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Stefan Klostermann, Christian Klein, Simon Patrick Keiser, Tanja Fauti, Estelle Marrer-Berger, Pablo Umaña
  • Patent number: 11976124
    Abstract: The present disclosure provides isolated monoclonal antibodies or an antigen-binding portion thereof that specifically bind to CD40 preferably human CD40 with high affinity, and that function as CD40 agonists. The disclosed invention also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention, hybridoma, and methods for expressing the antibodies of the disclosed invention are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating humoral and cellular immune responses, as well as methods for treating cancer using an anti-CD40 agonist antibody of the disclosed invention.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: May 7, 2024
    Assignee: ABVISION, INC.
    Inventors: Chang-Hsin Chen, Gloria Zhang, Guochen Yan, Cheng-Chi Chao
  • Patent number: 11976128
    Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: May 7, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael A. Curran, Ashvin R. Jaiswal, Dongxing Zha, Kui Voo, Carlo Toniatti, Bianka Prinz, Nadthakarn Boland